PreveCeutical Medical Partners to Develop CBD Sol-Gels & Novel Diabetes Treatment, Plans to Go Public
April 24th, 2017
News, Top News
Many pharmaceutical companies are focused on treating later-stage diseases, but these solutions can be both costly for the medical system and ineffective for patients. Preventive medicine is rapidly emerging as an effective way to help lower cost and improve patient outcomes by focusing on preventing the disease from occurring rather than simply treating its side-effects or prolonging life expectancy by a few years.
In this article, we will take a look at PreveCeutical Medical Inc.’s research and option agreement with UniQuest Pty Limited to develop preventive medicines like a novel cannabinoid delivery system and a pharmaceutical targeting individuals at risk for diabetes.
PreveCeutical Medical is currently engaged in an amalgamation agreement that would take the company public in the coming months. Please click here to sign up for a going-public alert and to receive the company’s presentation.
New CBD Delivery System
Cannabidiol (CBD) has become an increasing area of focus for researchers. According to Google Scholar, which aggregates research publications, there have been over 600 papers published covering CBD since the beginning of the year. ProjectCBD has classified these studies into over 50 different medical conditions, including conditions like autism, cancer, heart disease, obesity, schizophrenia, and various skin conditions like acne.
A major problem impacting cannabinoid-based medications is bioavailability since first-pass metabolism typically prevents the compounds from reaching the body. In fact, some studies have shown that the bioavailability of certain cannabinoids range from an average of just 30% when smoked to only 5% when taken orally via capsule or in oil-infused edible products. The National Institutes of Health sees effective drug delivery systems as a key issue to solve.
PreveCeutical Medical has engaged UniQuest to develop CBD-infused soluble gels – or sol-gels – as a way to enhance the bioavailability of CBD. Sprayed into the nasal passages, these sol-gels become liquid upon administration and rapidly gel upon contact with nasal mucosa, and they can be easily administered by patients without medical supervision.
The direct nose-to-brain central nervous system delivery method means that the compounds bypass the liver and related metabolism issues, solving some of the biggest problems with cannabinoid delivery. Another advantage of the gel is that it stays in the nasal passages, slowly releasing the CBD active, for up to seven days. The ease of application and its long-lasting effects could be attractive for patients when compared to trying to remember to take pills four times a day.
Dual-Gene Therapy for Diabetes
Diabetes affects over 30 million Americans – or roughly a tenth of the population – with more about a third of those individuals undiagnosed. A further 86 million Americans over 20 years old have so-called prediabetes with 1.4 million new cases of diabetes diagnosed each year, according to the American Diabetes Association. These trends have made diabetes the seventh leading cause of death with about a quarter million death certificates listing it as a cause.
Type II diabetes and obesity often go hand-in-hand since insulin-resistance is often seen alongside conditions like metabolic syndrome – a group of conditions involving excess weight, high blood pressure, and elevated triglycerides in the blood. The close relationship between diabetes and obesity suggests that researchers should focus on therapies that address both of the underlying causes to develop the most effective treatments.
PreveCeutical Medical is working with UniQuest to develop a dual-gene therapy that targets both obesity and diabetes with a single target gene. The goal is to develop a smart siRNA therapeutic that effectively silences genes of clinical relevance and interest. The assessment of safety and efficacy in appropriate preclinical models of diabetes could pave the way for broader preclinical and clinical safety and efficacy evaluations over time.
PreveCeutical Medical Inc. is uniquely positioned in the preventive medicine industry. With its recent agreement with UniQuest, the company is poised to begin developing innovative products with the CBD and gene therapy markets over the near-term. Investors may want to keep a close eye on the company given the enormous potential end markets of its products and the company’s plans to soon enter the public markets.
Interested parties have a great opportunity to learn more this week. Information on the Uniquest projects will be presented by Dr. Makarand Jawadekar, Chief Science Officer, and Dr. Harendra (Harry) Parekh at PMI’s presentation on April 27, 2017.
Venue: The Fairmont Waterfront Hotel (900 Canada Pl, Vancouver, BC V6C 3L5), Malaspina Room
Date: Thursday, April 27, 2017
Time: 1:30 p.m. PDT to 6:00 p.m. PDT
Confirm your attendance, register by clicking here: https://preveceutical-presentation-2017.eventbrite.ca/
For more information, visit the company’s website at www.preveceutical.com.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.